STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Pharmaceuticals
drugs-3

MIRA Pharmaceuticals Advances Ketamir-2: A Safe Step Forward in Neuropathic Pain Treatment

byLuca Blaumann
December 10, 2024
in Pharmaceuticals, Small-Cap
Reading Time: 4 mins read
Share on TwitterShare on LinkedIn

Favorable safety results pave the way for Phase 1 human trials in early 2025, offering hope for millions seeking non-addictive pain relief solutions

MIRA Pharmaceuticals (MIRA), a preclinical-stage pharmaceutical company, has announced a critical advancement in its development of Ketamir-2, a novel oral ketamine analog designed to treat neuropathic pain. Recent safety studies affirm the drug’s strong safety profile, enabling the company to progress toward Phase 1 human trials in early 2025.

A Milestone in Neuropathic Pain Drug Development

“This milestone reflects our commitment to advancing Ketamir-2 as a safe and effective treatment for neuropathic pain,” said Erez Aminov, CEO and Chairman of MIRA Pharmaceuticals. “Our focus on safety positions us to attract strategic partnerships or pursue potential mergers and acquisitions as we move forward.”

The findings mark a significant step for MIRA, as safety concerns account for nearly 40% of drug failures during clinical development. By addressing this critical challenge early, the company reduces risk and strengthens its case for regulatory approval.

Preclinical Data Highlights Ketamir-2’s Safety

Comprehensive preclinical studies revealed no significant safety concerns for Ketamir-2 across key physiological systems:

  • Cardiovascular Safety: No adverse effects at therapeutic doses in canine studies.
  • Central Nervous System (CNS): Favorable outcomes in rats, with no significant changes at therapeutic doses. High-dose effects were limited, transient, and non-disruptive.
  • Respiratory Function: No respiratory-related effects in rats, even at higher doses.
  • 14-Day Toxicology: Ketamir-2 was well-tolerated at daily doses up to 200 mg/kg in dogs.
  • Ames Test: The drug was confirmed as non-mutagenic, underscoring its safe profile.

These results collectively validate Ketamir-2’s potential as a non-addictive alternative for managing neuropathic pain, a condition that affects millions of people worldwide.

The Road to Phase 1 Human Trials

Building on the success of these preclinical studies, MIRA aims to launch its Phase 1 human trials in the first quarter of 2025. These trials will assess Ketamir-2’s safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants.

Notably, the trials will incorporate a battery of pain and psychosis tests, offering valuable insights into the drug’s therapeutic effects. Initial results are anticipated by the second quarter of 2025.

Following Phase 1, the company plans to initiate a Phase IIa proof-of-concept study in late 2025. This study will focus on patients with neuropathic pain, with results expected in early 2026.

Addressing an Urgent Medical Need

Neuropathic pain remains a challenging condition to treat, as many existing therapies carry risks of addiction or intolerable side effects. Ketamir-2’s development represents a potential paradigm shift in managing this condition, offering hope to patients seeking safer, more effective options.

Dr. Itzchak Angel, MIRA’s Chief Scientific Advisor, emphasized the broader implications of this development:
“This is a pivotal moment for both MIRA Pharmaceuticals and the millions of patients who suffer from neuropathic pain. Ketamir-2 holds the promise of being a groundbreaking treatment, addressing a significant unmet medical need with its strong safety profile and potential efficacy.”

Financial and Strategic Strength

MIRA’s financial position further bolsters its ability to achieve clinical milestones. The company is actively exploring non-dilutive funding opportunities to accelerate development and enhance Ketamir-2’s therapeutic impact.

By demonstrating Ketamir-2’s safety and positioning it for clinical success, MIRA not only advances its mission but also strengthens its appeal to potential partners and investors.

MIRA Pharmaceuticals’ progress with Ketamir-2 underscores the company’s commitment to addressing critical gaps in neuropathic pain management. With a strong safety profile validated through rigorous preclinical testing, the company is poised to move confidently into human trials.

As the global demand for non-addictive pain treatments grows, Ketamir-2’s development represents a beacon of hope for millions. MIRA’s innovative approach and strategic focus position it as a leader in this transformative field of medicine.

Clickhereto read the original press release.

You might like this article:Mondelez Eyes Hershey in Potential Blockbuster Deal

Tags: BreakingGrowthMIRAMoversNewspharmaStock Market
Previous Post

Mondelez Eyes Hershey in Potential Blockbuster Deal

Next Post

Oracle Shares Tumble as Revenue Falls Short, Cloud Competition Intensifies

Related Posts

scientist

Scienture Launches Commercial Sales of Arbli™, the First FDA-Approved Ready-to-Use Losartan Suspension

byLuca Blaumann
October 23, 2025
0

$256 million U.S. market opportunity drives expansion as company kicks off multi-channel promotional campaign Scienture Holdings (SCNX) announced the official...

chemistry-2

Replimune Reports Promising New Data for Acral Melanoma Treatment at ESMO 2025

byLuca Blaumann
October 20, 2025
0

RP1 combined with nivolumab shows meaningful tumor response in rare and aggressive skin cancer Replimune Group (REPL), a clinical-stage biotechnology...

Praxis Announces Breakthrough Phase 3 Results for Ulixacaltamide in Essential Tremor Treatment

byLuca Blaumann
October 16, 2025
0

Positive data from Essential3 program marks major step toward first targeted therapy for millions living with essential tremor Praxis Precision...

Next Post
investing

Oracle Shares Tumble as Revenue Falls Short, Cloud Competition Intensifies

Latest News

Alphabet Tops $100 Billion Quarter as AI Cloud Deals Power Record Growth

Microsoft Reports Strong Q3 Results Driven by Cloud and AI Momentum

Meta Beats on Revenue, Misses EPS as One-Time Tax Charge Weighs on Q3

Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240

Orion Group Holdings Delivers Strong Q3 Results and Raises 2025 Guidance

Based on Your Interest

nvidia-chip
Artificial Intelligence

Nvidia Partners with U.S. Department of Energy to Build Seven AI Supercomputers

October 28, 2025
investing
Artificial Intelligence

Qualcomm Enters the AI Data Center Battle with Powerful New AI200 and AI250 Chips

October 27, 2025
Biotechnology

Co-Diagnostics Expands Global Reach with New Saudi Joint Venture

October 27, 2025

Recommended

Artificial Intelligence

Datavault AI and Wellgistics Partner to Revolutionize Prescription Tracking with Blockchain Technology

October 24, 2025
Large-Cap

AMD Shares Surge as IBM Taps Its Chips for Quantum Computing Breakthrough

October 24, 2025
Large-Cap

Intel Surges After Strong Q3 Earnings Beat, But Manufacturing Challenges Remain

October 23, 2025
Auto Manufacturers

Ford Beats Q3 Estimates but Cuts 2025 Outlook Following Supplier Fire

October 23, 2025
Biotechnology

Scienture Launches Commercial Sales of Arbli™, the First FDA-Approved Ready-to-Use Losartan Suspension

October 23, 2025
Stoxpo

Follow us on social media:

Highlights

  • Alphabet Tops $100 Billion Quarter as AI Cloud Deals Power Record Growth
  • Microsoft Reports Strong Q3 Results Driven by Cloud and AI Momentum
  • Meta Beats on Revenue, Misses EPS as One-Time Tax Charge Weighs on Q3
  • Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240
  • Orion Group Holdings Delivers Strong Q3 Results and Raises 2025 Guidance

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

Alphabet Tops $100 Billion Quarter as AI Cloud Deals Power Record Growth

October 29, 2025

Microsoft Reports Strong Q3 Results Driven by Cloud and AI Momentum

October 29, 2025
investing

Meta Beats on Revenue, Misses EPS as One-Time Tax Charge Weighs on Q3

October 29, 2025
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.